Search

Your search keyword '"Yoshimatsu Kentaro"' showing total 143 results

Search Constraints

Start Over You searched for: Author "Yoshimatsu Kentaro" Remove constraint Author: "Yoshimatsu Kentaro"
143 results on '"Yoshimatsu Kentaro"'

Search Results

1. Genetic and chemical inhibition of IRF5 suppresses pre-existing mouse lupus-like disease

2. Lyn Kinase Suppresses the Transcriptional Activity of IRF5 in the TLR-MyD88 Pathway to Restrain the Development of Autoimmunity

3. Supplemental Materials and Methods from M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

4. Supplemental Figure 2 from M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

5. Supplemental Figure Legends from M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

6. Supplemental Figure 3 from M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

7. Supplemental Table 1 from M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

9. Supplemental Figure 4 from M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

10. Supplemental Figure 1 from M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

18. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors

19. M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers

20. A critical link between Lyn-mediated suppression of the TLR-MyD88-IRF5 pathway and the development of SLE-like disease

21. Erratum to “Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products” [Biologicals 43 (5) (2015) 283–297]

22. Report of the international conference on regulatory endeavors towards the sound development of human cell therapy products

23. Purification and cDNA cloning of a novel factor produced by a human T-cell hybridoma: Sequence homology with animal lectins

25. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

26. In Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds

27. Efficacy of Oral E1210, a New Broad-Spectrum Antifungal with a Novel Mechanism of Action, in Murine Models of Candidiasis, Aspergillosis, and Fusariosis

30. Synthesis and Evaluation of Novel Pyrimido-Acridone, -Phenoxadine, and -Carbazole as Topoisomerase II Inhibitors

32. A novel carbazole topoisomerase II poison, ER‐37328: potent tumoricidal activity against human solid tumors in vitro and in vivo

Catalog

Books, media, physical & digital resources